靶点- |
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期1980-11-28 |
Therapeutic Equivalence (non-inferiority), Randomized, Observer-blind, two Parallel Group, Clinical Trial for Comparing the Efficacy and Tolerability of a Generic Formulation of Vaginal Ovule containing Clindamycin 100 mg/ovule versus Dalacin® 100 mg Vaginal Ovules (Pfizer©) in patients with Bacterial Vaginosis - Therapeutic equivalence trial between two formulations of clindamycin 100mg vaginal ovules
A Pivotal, Open-label, Balanced, Randomised, Two-treatment, Two-sequence, Two-period, Two-way Crossover, Single Oral Dose Bioequivalence Study of Rosuvastatin/ Verisfield 20 mg Film-coated Tablets Versus Crestor/ AstraZeneca 20 mg Film-coated Tablets in Healthy Adults Under Fasting Conditions
The purpose of this study is to determine the bioequivalence of Rosuvastatin/ Verisfield 20 mg film-coated tablets and Crestor™/ AstraZeneca 20 mg film-coated tablets.
Comparative Randomized, Single Dose, Two-Way Crossover Open Label Bioequivalence Study of Terix Labs Ltd Metronidazole Benzoate (400 mg Metronidazole Per Sachet Oral Granules) Versus Zentiva Flagyl™ 400 mg Tablets (400 mg Metronidazole Per Film Coated Tablet), After An Oral Administration Of 400 mg to Healthy Adults Under Fasting Conditions
The purpose of this study is to determine the bioequivalence of Metronidazole benzoate (400 mg metronidazole per sachet oral granules)/Terix Labs Ltd and Flagyl™ 400 mg Tablets (400 mg metronidazole per film coated tablet)/Zentiva.
100 项与 Verisfield (UK) Ltd. 相关的临床结果
0 项与 Verisfield (UK) Ltd. 相关的专利(医药)
100 项与 Verisfield (UK) Ltd. 相关的药物交易
100 项与 Verisfield (UK) Ltd. 相关的转化医学